Polyclonal Antibody to Gastric Inhibitory Polypeptide (GIP) Homo sapiens (Human) Polyclonal antibody

Incretin hormone; Glucose Dependent Insulinotropic Peptide

Add to Cart Distributors
Overview
Properties
  • SourcePolyclonal antibody preparation, Host Rabbit
  • Ig Type IgG, Potency n/a
  • PurificationAntigen-specific affinity chromatography followed by Protein A affinity chromatography
  • LabelNone
  • Immunogen RPA882Hu01-Recombinant Gastric Inhibitory Polypeptide (GIP)
  • Buffer Formulation0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
  • TraitsLiquid, Concentration 0.5mg/mL
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Polyclonal Antibody to Gastric Inhibitory Polypeptide (GIP) Packages (Simulation)
  • Polyclonal Antibody to Gastric Inhibitory Polypeptide (GIP) Packages (Simulation)
  • Polyclonal Antibody to Gastric Inhibitory Polypeptide (GIP) IHC Images
  • PAA882Hu01.jpg Figure. Western Blot; Sample: Recombinant GIP, Human.
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Specifity

The antibody is a rabbit polyclonal antibody raised against GIP. It has been selected for its ability to recognize GIP in immunohistochemical staining and western blotting.

Usage

Western blotting: 0.01-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.

Storage

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Giveaways

Citations

  • The anti-hyperglycemic efficacy of a lipid-lowering drug Daming capsule and the underlyingsignaling mechanisms in a rat model of diabetes mellitus.pubmed:27721485
  • The Effects of Duodenojejunal Omega Switch in Combination with High-Fat Diet and Control Diet on Incretins, Body Weight, and Glucose Tolerance in Sprague-Dawley Rats.pubmed:28840471
  • Preserving Duodenal-Jejunal (Foregut) Transit Does Not Impair Glucose Tolerance and Diabetes Remission Following Gastric Bypass in Type 2 Diabetes Sprague …Pubmed:29098544
  • Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
  • Low AS160 and high SGK basal phosphorylation associates with impaired incretin profile and type 2 diabetes in adipose tissue of obese patientsPubmed: 31734225
  • The Leading Role of Peptide Tyrosine Tyrosine in Glycemic Control After Roux-en-Y Gastric Bypass in RatsPubmed: 31701411
  • Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetesPubmed:35251693

Recommend products